Provention Bio

About:

Provention Bio is a clinical stage biopharmaceutical dedicated to sourcing, developing, and commercializing novel therapeutics.

Website: http://www.proventionbio.com

Twitter/X: proventionbio

Top Investors: Sanofi, Hercules Capital, Johnson & Johnson Robotics and Digital Solutions, JDRF T1D Fund, Armistice Capital

Description:

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses. Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.